Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Infinity Pharmaceuti (NQ: INFI )

0.1802 +0.0001 (+0.06%)
Streaming Delayed Price Updated: 1:09 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Infinity Pharmaceuti

< Previous 1 2 Next >
Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Reports Full Year 2022 Financial Results
From Infinity Pharmaceuticals, Inc.
Via Business Wire
INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI
From Kahn Swick & Foti, LLC
Via Business Wire
INFI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Infinity Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
From MEI Pharma, Inc.
Via Business Wire
Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and Webcast
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity to Participate in Oppenheimer’s Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macrophage-directed Therapies Summit
From Infinity Pharmaceuticals, Inc.
Via Business Wire
Infinity Pharmaceuticals Appoints Robert Ilaria, Jr., M.D., as Chief Medical Officer and Brian Schwartz, M.D., to Its Board of Directors
From Infinity Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.